|
|
|
|
| LEADER |
02581nma a2200625 u 4500 |
| 001 |
EB001992532 |
| 003 |
EBX01000000000000001155434 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a 9783039435302
|
| 020 |
|
|
|a 9783039435296
|
| 020 |
|
|
|a books978-3-03943-530-2
|
| 100 |
1 |
|
|a Wink, Joachim
|
| 245 |
0 |
0 |
|a Actinobacteria and Myxobacteria
|h Elektronische Ressource
|b Important Resources for Novel Antibiotics
|
| 260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2020
|
| 300 |
|
|
|a 1 electronic resource (270 p.)
|
| 653 |
|
|
|a antioxidant
|
| 653 |
|
|
|a Ebola
|
| 653 |
|
|
|a HIV
|
| 653 |
|
|
|a antimicrobial
|
| 653 |
|
|
|a marine actinobacteria
|
| 653 |
|
|
|a enzyme inhibition
|
| 653 |
|
|
|a polyketide synthases (PKSs)
|
| 653 |
|
|
|a GC-MS
|
| 653 |
|
|
|a polyketides
|
| 653 |
|
|
|a hepatitis viruses
|
| 653 |
|
|
|a secondary metabolites
|
| 653 |
|
|
|a Streptomyces sp.
|
| 653 |
|
|
|a uncultured
|
| 653 |
|
|
|a antibiotic biosynthesis
|
| 653 |
|
|
|a translation inhibitors
|
| 653 |
|
|
|a secondary metabolite
|
| 653 |
|
|
|a actinomycetes
|
| 653 |
|
|
|a Research & information: general / bicssc
|
| 653 |
|
|
|a Biology, life sciences / bicssc
|
| 653 |
|
|
|a pyrrolopyrazines
|
| 653 |
|
|
|a new antibiotics
|
| 653 |
|
|
|a diversity
|
| 653 |
|
|
|a silent biosynthetic pathways
|
| 653 |
|
|
|a myxobacteria
|
| 653 |
|
|
|a Streptomyces
|
| 653 |
|
|
|a γ-butyrolactones
|
| 653 |
|
|
|a antivirals
|
| 653 |
|
|
|a cytotoxicity
|
| 653 |
|
|
|a HiTES
|
| 700 |
1 |
|
|a Wink, Joachim
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-03943-530-2
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/69411
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/3213
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 000
|
| 520 |
|
|
|a Bacterial infections cause millions of deaths globally, particularly in children and the elderly, and four of the 10 leading causes of death are infectious diseases in low- and middle-income countries. The continuous use of antibiotics has resulted in multi-resistant bacterial strains all over the world, such as Community-associated Methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum β-lactamases (ESBLs), and, as expected, hospitals have become breeding grounds for human-associated microorganisms, especially in critical care units.
|